Whittier Trust Co. Buys 1,779 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Whittier Trust Co. grew its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 4.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 41,804 shares of the medical instruments supplier’s stock after buying an additional 1,779 shares during the quarter. Whittier Trust Co. owned 0.06% of West Pharmaceutical Services worth $12,547,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Fidelis Capital Partners LLC bought a new position in shares of West Pharmaceutical Services during the first quarter valued at approximately $27,000. Northwest Investment Counselors LLC bought a new position in shares of West Pharmaceutical Services during the third quarter valued at approximately $30,000. Crewe Advisors LLC grew its stake in shares of West Pharmaceutical Services by 322.7% during the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 71 shares during the last quarter. Hazlett Burt & Watson Inc. bought a new position in shares of West Pharmaceutical Services during the first quarter valued at approximately $40,000. Finally, ORG Partners LLC boosted its holdings in shares of West Pharmaceutical Services by 820.0% in the first quarter. ORG Partners LLC now owns 138 shares of the medical instruments supplier’s stock valued at $55,000 after purchasing an additional 123 shares during the period. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Trading Down 1.6 %

Shares of NYSE WST traded down $4.55 during trading hours on Monday, reaching $288.77. The stock had a trading volume of 140,527 shares, compared to its average volume of 549,860. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. The firm has a market cap of $20.95 billion, a price-to-earnings ratio of 41.72, a P/E/G ratio of 10.46 and a beta of 1.01. The business’s fifty day moving average price is $299.96 and its two-hundred day moving average price is $324.95. West Pharmaceutical Services, Inc. has a 52-week low of $265.00 and a 52-week high of $413.70.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The firm had revenue of $702.10 million during the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The firm’s revenue for the quarter was down 6.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.11 EPS. Analysts expect that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current fiscal year.

Insider Transactions at West Pharmaceutical Services

In other news, VP Charles Witherspoon sold 1,029 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the transaction, the vice president now directly owns 1,478 shares of the company’s stock, valued at approximately $443,400. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.